Mr. Vijay Karwal
  • Independent Director
  • Chair of Audit Committee
  • Member of Nomination Committee
Mr. Vijay Karwal
Age (As on 31 Dec 2025)
  • 55 Years
Education
  • Association for Investment Management & Research / CFA Institute Current holder of Chartered Financial Analyst (CFA)
  • University of Groningen, The Netherlands M.Sc. in Monetary Economics
  • University of Southampton, United Kingdom Erasmus Scholar – Department of Accounting & Management Sciences
IOD Training
  • DAP No. 216/2024
Training
  • 2017- Harvard Business School Business Innovation Program in Global Healthcare
  • 2006 - Columbia University School of Business Negotiation Strategies and Decision Making Course
  • 1997 - New York University, Stern College of Business, Valuation course
Shared Held by Each Director (As on 30 Dec 2024)
  • None
Current position in the Company
  • Independent Director, Chair of Audit Committee and Member of Nomination Committee
Current position in other listed companies in Thailand
  • None
Current position in other companies
November 2025 - Present
  • Director, Non-Independent Non-Executive Director ม Dawn Medical Technologies (Singapore) / A leading MedTech commercialization platform in Asia, enhancing access to affordable, high-quality medical technology across Southeast Asia.
January 2025 - Present
  • Director, Non-Executive Independent Director, Member of Audit Committee, Chairman of Nomination and Remuneration Committee and Risk Management Committee, Member of CSR Committee, Strategic Advisory Committee, ESG Committee, and Management Committee, OneSource Specialty Pharma Limited (Bangalore, India) / a pure-play specialty pharmaceutical CDMO
November 2022 - Present
  • Director, Non-Independent Non-Executive Director, AffaMed Therapeutics (Hong Kong) / Developing pharmaceutical, and surgical products that address critical unmet medical needs in ophthalmology for patients in Greater China, Asia and around the world
May 2021 - Present
  • Managing Director, CBC Group (Singapore) / Asia’s largest healthcare- focused asset management, investing across pharmaceuticals, biotechnology, medical technology and healthcare services.
May 2021 - April 2024
  • Chief Executive Officer & Chief Financial Officer, AffaMed Therapeutics (Hong Kong)
August 2018 - May 2021
  • Managing Director, Head of Healthcare Investment Banking, Asia ex-Japan, Nomura International (Hong Kong)
Present directorship / management in other businesses with potential conflict of interest
  • None
Meeting attendance for the past fiscal year
  • Board of Director’s meeting attended 7 out of 7 meetings
  • Audit Committee’s meeting: attended 4 out of 4 meetings
  • Nomination Committee’s meeting: attended 2out of 2 meetings
Type of Directorship
  • Independent Director
Number of years held the director position
  • 3 years, since May 13, 2021 in Mega Lifesciences Public Company Limited
Qualification of Independent Director and member of Audit Committee
  • Possesses all qualifications pursuant to definitions of Independent Director and member of Audit Committee of the Company which are in accordance with the relevant requirements of the Office of Securities and Exchange Commission and the Stock Exchange of Thailand
Back